Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.04
LLY's Cash to Debt is ranked higher than
61% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. LLY: 1.04 )
LLY' s 10-Year Cash to Debt Range
Min: 0.11   Max: 1.64
Current: 1.04

0.11
1.64
Equity to Asset 0.50
LLY's Equity to Asset is ranked higher than
56% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.60 vs. LLY: 0.50 )
LLY' s 10-Year Equity to Asset Range
Min: 0.23   Max: 0.5
Current: 0.5

0.23
0.5
Interest Coverage 33.54
LLY's Interest Coverage is ranked higher than
62% of the 460 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 88.77 vs. LLY: 33.54 )
LLY' s 10-Year Interest Coverage Range
Min: 6.92   Max: 63.3
Current: 33.54

6.92
63.3
F-Score: 7
Z-Score: 4.31
M-Score: -2.61
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 23.24
LLY's Operating margin (%) is ranked higher than
92% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.34 vs. LLY: 23.24 )
LLY' s 10-Year Operating margin (%) Range
Min: -6.29   Max: 33.63
Current: 23.24

-6.29
33.63
Net-margin (%) 20.27
LLY's Net-margin (%) is ranked higher than
92% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.48 vs. LLY: 20.27 )
LLY' s 10-Year Net-margin (%) Range
Min: -10.17   Max: 33.87
Current: 20.27

-10.17
33.87
ROE (%) 26.57
LLY's ROE (%) is ranked higher than
98% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. LLY: 26.57 )
LLY' s 10-Year ROE (%) Range
Min: -30.76   Max: 54.28
Current: 26.57

-30.76
54.28
ROA (%) 13.29
LLY's ROA (%) is ranked higher than
96% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.94 vs. LLY: 13.29 )
LLY' s 10-Year ROA (%) Range
Min: -7.09   Max: 21.22
Current: 13.29

-7.09
21.22
ROC (Joel Greenblatt) (%) 67.34
LLY's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 732 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.50 vs. LLY: 67.34 )
LLY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -14.86   Max: 85.23
Current: 67.34

-14.86
85.23
Revenue Growth (%) 0.70
LLY's Revenue Growth (%) is ranked higher than
61% of the 552 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. LLY: 0.70 )
LLY' s 10-Year Revenue Growth (%) Range
Min: 0.6   Max: 13
Current: 0.7

0.6
13
EBITDA Growth (%) -1.70
LLY's EBITDA Growth (%) is ranked higher than
66% of the 507 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. LLY: -1.70 )
LLY' s 10-Year EBITDA Growth (%) Range
Min: -76.9   Max: 437.2
Current: -1.7

-76.9
437.2
EPS Growth (%) -1.90
LLY's EPS Growth (%) is ranked higher than
68% of the 510 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. LLY: -1.90 )
LLY' s 10-Year EPS Growth (%) Range
Min: -13.7   Max: 20
Current: -1.9

-13.7
20
» LLY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

LLY Guru Trades in Q1 2013

Ken Fisher 3,900 sh (New)
Joel Greenblatt 3,961 sh (New)
Jeremy Grantham 3,857,862 sh (+78.18%)
Pioneer Investments 951,265 sh (+54.3%)
Steven Cohen 238,226 sh (+40.88%)
Jim Simons 10,555,805 sh (+30.18%)
Manning & Napier Advisors, Inc 179,863 sh (+8%)
Dodge & Cox 36,060 sh (unchged)
Vanguard Health Care Fund 15,364,300 sh (unchged)
Ray Dalio Sold Out
Louis Moore Bacon Sold Out
Bill Frels 284,878 sh (-0.57%)
Chris Davis 283,709 sh (-2.73%)
PRIMECAP Management 46,844,876 sh (-3.65%)
Murray Stahl 36,136 sh (-5.43%)
Charles Brandes 2,037,064 sh (-9.02%)
Mario Gabelli 142,500 sh (-13.48%)
Paul Tudor Jones 8,800 sh (-13.73%)
George Soros 55,000 sh (-45%)
John Hussman 601,000 sh (-57.1%)
Signature Select Canadian Fund 384,900 sh (-58.95%)
HOTCHKIS & WILEY 407,650 sh (-73.82%)
» More
Q2 2013

LLY Guru Trades in Q2 2013

Joel Greenblatt 39,411 sh (+894.98%)
Jeremy Grantham 6,254,352 sh (+62.12%)
Paul Tudor Jones 10,700 sh (+21.59%)
Jim Simons 12,326,205 sh (+16.77%)
John Hussman 701,000 sh (+16.64%)
Chris Davis 298,809 sh (+5.32%)
PRIMECAP Management 48,900,865 sh (+4.39%)
Vanguard Health Care Fund 15,923,800 sh (+3.64%)
Manning & Napier Advisors, Inc 185,462 sh (+3.11%)
Charles Brandes 2,060,252 sh (+1.14%)
Ken Fisher Sold Out
George Soros Sold Out
HOTCHKIS & WILEY Sold Out
Dodge & Cox 35,960 sh (-0.28%)
Murray Stahl 35,960 sh (-0.49%)
Bill Frels 282,498 sh (-0.84%)
Pioneer Investments 883,752 sh (-7.1%)
Mario Gabelli 127,000 sh (-10.88%)
Steven Cohen 188,414 sh (-20.91%)
» More
Q3 2013

LLY Guru Trades in Q3 2013

David Dreman 4,290 sh (New)
Richard Pzena 433,250 sh (New)
Ray Dalio 19,039 sh (New)
Joel Greenblatt 46,761 sh (+18.65%)
Charles Brandes 2,409,134 sh (+16.93%)
Vanguard Health Care Fund 18,617,000 sh (+16.91%)
Jeremy Grantham 7,012,820 sh (+12.13%)
Bill Frels 296,659 sh (+5.01%)
PRIMECAP Management 50,846,997 sh (+3.98%)
Manning & Napier Advisors, Inc 185,891 sh (+0.23%)
Murray Stahl 35,960 sh (unchged)
Louis Moore Bacon 200,000 sh (unchged)
Chris Davis Sold Out
Signature Select Canadian Fund Sold Out
Dodge & Cox 35,760 sh (-0.56%)
Pioneer Investments 873,546 sh (-1.15%)
Mario Gabelli 124,500 sh (-1.97%)
Steven Cohen 157,959 sh (-16.16%)
Jim Simons 8,287,805 sh (-32.76%)
Paul Tudor Jones 6,600 sh (-38.32%)
John Hussman 10,000 sh (-98.57%)
» More
Q4 2013

LLY Guru Trades in Q4 2013

Ken Fisher 4,429 sh (New)
Joel Greenblatt 141,121 sh (+201.79%)
Ray Dalio 48,239 sh (+153.37%)
Paul Tudor Jones 10,400 sh (+57.58%)
Vanguard Health Care Fund 22,895,000 sh (+22.98%)
Charles Brandes 2,711,949 sh (+12.57%)
David Dreman 4,760 sh (+10.96%)
Bill Frels 303,237 sh (+2.22%)
PRIMECAP Management 51,548,425 sh (+1.38%)
John Hussman 10,000 sh (unchged)
Dodge & Cox 35,760 sh (unchged)
Pioneer Investments 871,998 sh (-0.18%)
Richard Pzena 432,150 sh (-0.25%)
Mario Gabelli 123,900 sh (-0.48%)
Jeremy Grantham 6,302,844 sh (-10.12%)
Murray Stahl 30,660 sh (-14.74%)
Jim Simons 7,061,700 sh (-14.79%)
Manning & Napier Advisors, Inc 121,840 sh (-34.46%)
Steven Cohen 26,175 sh (-83.43%)
» More
» Details

Insider Trades

Latest Guru Trades with LLY

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2013-12-31 Add 22.98%0.67%$47.65 - $51.34 $ 60.4321%22895000
Charles Brandes 2013-12-31 Add 12.57%0.19%$47.65 - $51.34 $ 60.4321%2711949
Joel Greenblatt 2013-12-31 Add 201.79%0.11%$47.65 - $51.34 $ 60.4321%141121
Ray Dalio 2013-12-31 Add 153.37%0.01%$47.65 - $51.34 $ 60.4321%48239
John Hussman 2013-09-30 Reduce -98.57%1.58%$49.92 - $54.96 $ 60.4315%10000
Vanguard Health Care Fund 2013-09-30 Add 16.91%0.46%$49.92 - $54.96 $ 60.4315%18617000
Charles Brandes 2013-09-30 Add 16.93%0.23%$49.92 - $54.96 $ 60.4315%2409134
PRIMECAP Management 2013-09-30 Add 3.98%0.13%$49.92 - $54.96 $ 60.4315%50846997
David Dreman 2013-09-30 New Buy0.02%$49.92 - $54.96 $ 60.4315%4290
Ray Dalio 2013-09-30 New Buy0.01%$49.92 - $54.96 $ 60.4315%19039
John Hussman 2013-06-30 Add 16.64%0.23%$49.06 - $58.33 $ 60.4311%701000
PRIMECAP Management 2013-06-30 Add 4.39%0.14%$49.06 - $58.33 $ 60.4311%48900865
Joel Greenblatt 2013-06-30 Add 894.98%0.07%$49.06 - $58.33 $ 60.4311%39411
George Soros 2013-06-30 Sold Out 0.04%$49.06 - $58.33 $ 60.4311%0
John Hussman 2013-03-31 Reduce -57.1%1.03%$49.32 - $56.79 $ 60.4312%601000
George Soros 2013-03-31 Reduce -45%0.03%$49.32 - $56.79 $ 60.4312%55000
Joel Greenblatt 2013-03-31 New Buy0.01%$49.32 - $56.79 $ 60.4312%3961
Ray Dalio 2013-03-31 Sold Out 0.01%$49.32 - $56.79 $ 60.4312%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Eli Lilly and Company

Prolific Selling - Hussman’s High-Impact Moves Mirror Insiders
Guru John Hussman made over a hundred reductions and sellouts in the third quarter. The four highest-impact sells made by Hussman Econometrics Advisors include: Eli Lilly and Company (LLY), Gap Inc. (GPS), Time Warner Cable Inc. (TWC) and Urban Outfitters Inc. (URBN). Here are company updates and the details on Hussman’s trading that seems to track with very active insider selling in all four companies. Read more...
Renaissance Man Jim Simons - A Tale of Three Pharmaceuticals and Remarkable Gains
In 1982 Guru Jim Simons founded Renaissance Technologies, an investment management company known for hiring mathematicians and physicists and adhering to mathematical and statistical methods to produce superior returns. One of the world's most successful hedge funds, the private investment firm has over $20 billion under management. The Renaissance Technologies portfolio currently lists 2,848 stocks, 750 of them new, a quarter-over-quarter turnover of 42%, and a total value of $41.2 billion. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 14.00
LLY's P/E(ttm) is ranked higher than
89% of the 528 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.60 vs. LLY: 14.00 )
LLY' s 10-Year P/E(ttm) Range
Min: 7.46   Max: 51.42
Current: 14

7.46
51.42
P/B 3.83
LLY's P/B is ranked higher than
55% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.84 vs. LLY: 3.83 )
LLY' s 10-Year P/B Range
Min: 2.52   Max: 9.04
Current: 3.83

2.52
9.04
P/S 2.86
LLY's P/S is ranked higher than
59% of the 722 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.99 vs. LLY: 2.86 )
LLY' s 10-Year P/S Range
Min: 1.49   Max: 6.44
Current: 2.86

1.49
6.44
PFCF 14.63
LLY's PFCF is ranked higher than
88% of the 330 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.86 vs. LLY: 14.63 )
LLY' s 10-Year PFCF Range
Min: 5.16   Max: 452.77
Current: 14.63

5.16
452.77
EV-to-EBIT 12.57
LLY's EV-to-EBIT is ranked higher than
80% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.45 vs. LLY: 12.57 )
LLY' s 10-Year EV-to-EBIT Range
Min: 5.9   Max: 39
Current: 12.57

5.9
39
PEG 35.50
LLY's PEG is ranked lower than
68% of the 312 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.74 vs. LLY: 35.50 )
LLY' s 10-Year PEG Range
Min: 0.16   Max: 130
Current: 35.5

0.16
130
Shiller P/E 18.89
LLY's Shiller P/E is ranked higher than
78% of the 362 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.59 vs. LLY: 18.89 )
LLY' s 10-Year Shiller P/E Range
Min: 12.57   Max: 29.28
Current: 18.89

12.57
29.28

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.20
LLY's Dividend Yield is ranked higher than
93% of the 419 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.38 vs. LLY: 3.20 )
LLY' s 10-Year Dividend Yield Range
Min: 1.8   Max: 6.79
Current: 3.2

1.8
6.79
Dividend Payout 0.54
LLY's Dividend Payout is ranked higher than
58% of the 367 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. LLY: 0.54 )
LLY' s 10-Year Dividend Payout Range
Min: 0.33   Max: 0.86
Current: 0.54

0.33
0.86
Yield on cost (5-Year) 3.20
LLY's Yield on cost (5-Year) is ranked higher than
82% of the 430 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.42 vs. LLY: 3.20 )
LLY' s 10-Year Yield on cost (5-Year) Range
Min: 1.8   Max: 6.79
Current: 3.2

1.8
6.79
Share Buyback Rate 0.60
LLY's Share Buyback Rate is ranked higher than
88% of the 483 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.70 vs. LLY: 0.60 )
LLY' s 10-Year Share Buyback Rate Range
Min: 1   Max: -0.6
Current: 0.6

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.07
LLY's Price/Tangible Book is ranked higher than
50% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.10 vs. LLY: 5.07 )
LLY' s 10-Year Price/Tangible Book Range
Min: 4.28   Max: 34.18
Current: 5.07

4.28
34.18
Price/DCF (Projected) 1.07
LLY's Price/DCF (Projected) is ranked higher than
88% of the 346 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. LLY: 1.07 )
LLY' s 10-Year Price/DCF (Projected) Range
Min: 0.75   Max: 3.48
Current: 1.07

0.75
3.48
Price/Median PS Value 1.07
LLY's Price/Median PS Value is ranked higher than
80% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.10 vs. LLY: 1.07 )
LLY' s 10-Year Price/Median PS Value Range
Min: 0.62   Max: 4
Current: 1.07

0.62
4
Price/Peter Lynch Fair Value 0.57
LLY's Price/Peter Lynch Fair Value is ranked higher than
94% of the 145 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. LLY: 0.57 )
LLY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.43   Max: 3.55
Current: 0.57

0.43
3.55
Price/Graham Number 1.80
LLY's Price/Graham Number is ranked higher than
70% of the 461 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.20 vs. LLY: 1.80 )
LLY' s 10-Year Price/Graham Number Range
Min: 1.37   Max: 8.5
Current: 1.8

1.37
8.5
Earnings Yield (Greenblatt) 8.00
LLY's Earnings Yield (Greenblatt) is ranked higher than
83% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. LLY: 8.00 )
LLY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.6   Max: 16.9
Current: 8

2.6
16.9
Forward Rate of Return (Yacktman) 38.78
LLY's Forward Rate of Return (Yacktman) is ranked higher than
98% of the 532 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. LLY: 38.78 )
LLY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -18.1   Max: 79
Current: 38.78

-18.1
79

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:LEL.UK, LLY.Switzerland, LLY.France, LLY.Germany
Eli Lilly and Company was incorporated in 1901 in Indiana for the drug manufacturing business founded in Indianapolis, Indiana, in 1876. The Company discovers, develops, manufactures, and sells products in two business segments: human pharmaceutical products and animal health products. Its human pharmaceutical products include: Neuroscience products, Endocrinology products, Oncology products, cardiovascular products and other pharmaceuticals. Neuroscience products include: Cymbalta, Zyprexa, Strattera, Prozac, Symbyax, Amyvid; Endocrinology products: Humalog, Humulin, Byetta, Bydureon, Tradjenta, Jentadueto; Oncology products: Alimta, Gemzar, Erbitux; Cardiovascular products: Cialis, Effient, ReoPro, Adcirca, Livalo; Other pharmaceutical products: Vancocin HCl, Ceclor. Animal Health Products includes: Rumensin, a cattle feed additive that improves feed efficiency and growth and also controls and prevents coccidiosis; Tylan, an antibiotic used to control certain diseases in cattle, swine, and poultry; Micotil, Pulmotil, and Pulmotil AC, antibiotics used to treat respiratory disease in cattle, swine, and poultry, respectively; Paylean and Optaflexx, leanness and performance enhancers for swine and cattle, respectively Posilac, a protein supplement to improve milk productivity in dairy cows; Coban, Monteban, and Maxiban, anticoccidial agents for use in poultry; Apralan, an antibiotic used to control enteric infections in calves and swine; Surmax (sold as Maxus in some countries), a performance enhancer for swine and poultry. The Company competes with a number of multinational pharmaceutical companies, biotechnology companies, and generic pharmaceutical companies. Its operations are regulated extensively by numerous national, state, and local agencies. The FDA extensively regulates all aspects of manufacturing quality for human pharmaceuticals under its current Good Manufacturing Practices (cGMP) regulations.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide